Paxton Loke

14PUBLICATIONS
26CO-AUTHORS
Infant and child healthAllergyPacific Peoples mothers and babies health and wellbeingInnate immunityGender relations
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Nov 24, 2025
Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program.

T W Brettig, A Young, R Bhatia

|Oct 16, 2025
Probiotic oral immunotherapy for egg and milk allergy induces sustained unresponsiveness.

Melanie Lloyd, Paxton Loke, Kathy Nguyen

|Aug 22, 2025
Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy.

Sophie A Rosser, Melanie Lloyd, Paxton Loke

|Dec 26, 2024
Allergen-Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1-10 Years.

Sarah E Ashley, Melanie Lloyd, Paxton Loke

|Aug 05, 2024
Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) study.

Paxton Loke, Xiaofang Wang, Melanie Lloyd

|May 08, 2024
Longitudinal peanut and Ara h 2 specific-IgE, -IgG4, and -IgG4/-IgE ratios are associated with the natural resolution of peanut allergy in childhood.

Kayla M Parker, Thanh D Dang, Rushani Wijesuriya

Pageof 3

Frequent Collaborators

7 joint publications

Sarah E Ashley

4 joint publications

Mimi L K Tang

4 joint publications

Sophie Rosser

3 joint publications

Melanie Lloyd